Hong Kong Stock Movers: HBM Holdings-B Surges Over 7% in Early Trading on First-Half Revenue Growth and Profitability, Following Strategic Partnership with Sinopharm

Stock News10:52

HBM Holdings-B (02142) saw its shares jump more than 7% in early trading on the Hong Kong Stock Exchange. As of the time of writing, the stock was up 7.23% at HK$13.65, with a trading volume of HK$34.03 million.

The company recently issued a positive profit alert, forecasting revenue of US$120 million to US$125 million for the first half of 2026, with a net profit of US$62 million to US$67 million for the same period. The strong performance is attributed to ongoing strategic collaborations with global pharmaceutical giants, revenue from out-licensing innovative products and cooperative agreements, and robust growth in its antibody-related business through its subsidiary, Nona Biosciences.

Notably, in July, the company entered into a strategic partnership with China's Sinopharm to establish a joint innovation entity. The collaboration will focus on research and development in the field of innovative biologics, with strategic priorities covering areas such as oncology and immuno-inflammatory diseases. Under the terms of the agreement, both parties will share research and development costs and jointly own product rights.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121496757?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 10:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121496757","market":"sh","top_or_hot":-1,"title":"Hong Kong Stock Movers: HBM Holdings-B Surges Over 7% in Early Trading on First-Half Revenue Growth and Profitability, Following Strategic Partnership with Sinopharm","media":"Stock News","content":"<p><b>HBM Holdings-B</b> (<b>02142</b>) saw its shares jump more than 7% in early trading on the Hong Kong Stock Exchange. As of the time of writing, the stock was up 7.23% at HK$13.65, with a trading volume of HK$34.03 million.<br><br>The company recently issued a positive profit alert, forecasting revenue of US$120 million to US$125 million for the first half of 2026, with a net profit of US$62 million to US$67 million for the same period. The strong performance is attributed to ongoing strategic collaborations with global pharmaceutical giants, revenue from out-licensing innovative products and cooperative agreements, and robust growth in its antibody-related business through its subsidiary, <b>Nona Biosciences</b>.<br><br>Notably, in July, the company entered into a strategic partnership with China's <b>Sinopharm</b> to establish a joint innovation entity. The collaboration will focus on research and development in the field of innovative biologics, with strategic priorities covering areas such as oncology and immuno-inflammatory diseases. Under the terms of the agreement, both parties will share research and development costs and jointly own product rights.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movers: HBM Holdings-B Surges Over 7% in Early Trading on First-Half Revenue Growth and Profitability, Following Strategic Partnership with Sinopharm</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movers: HBM Holdings-B Surges Over 7% in Early Trading on First-Half Revenue Growth and Profitability, Following Strategic Partnership with Sinopharm\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-07 10:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>HBM Holdings-B</b> (<b>02142</b>) saw its shares jump more than 7% in early trading on the Hong Kong Stock Exchange. As of the time of writing, the stock was up 7.23% at HK$13.65, with a trading volume of HK$34.03 million.<br><br>The company recently issued a positive profit alert, forecasting revenue of US$120 million to US$125 million for the first half of 2026, with a net profit of US$62 million to US$67 million for the same period. The strong performance is attributed to ongoing strategic collaborations with global pharmaceutical giants, revenue from out-licensing innovative products and cooperative agreements, and robust growth in its antibody-related business through its subsidiary, <b>Nona Biosciences</b>.<br><br>Notably, in July, the company entered into a strategic partnership with China's <b>Sinopharm</b> to establish a joint innovation entity. The collaboration will focus on research and development in the field of innovative biologics, with strategic priorities covering areas such as oncology and immuno-inflammatory diseases. Under the terms of the agreement, both parties will share research and development costs and jointly own product rights.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1121496757","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121496757","pubTimestamp":1786071136,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HBM Holdings-B (02142) saw its shares jump more than 7% in early trading on the Hong Kong Stock Exchange. As of the time of writing, the stock was up 7.23% at HK$13.65, with a trading volume of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK1574":"生物医药B类股","VXUS":"国际股票ETF-Vanguard","02142":"和铂医药-B","BK1583":"高瓴概念","KCAI":"KraneShares China Alpha Index ETF","BK4588":"碎股"},"translate_title":"香港股市走势：与国药集团建立战略合作伙伴关系后，HBM Holdings-B 因上半年收入增长和盈利能力在早盘交易中飙升超过 7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KCAI":1,"VXUS":1,"02142":1},"content_text":"HBM Holdings-B (02142) saw its shares jump more than 7% in early trading on the Hong Kong Stock Exchange. As of the time of writing, the stock was up 7.23% at HK$13.65, with a trading volume of HK$34.03 million.The company recently issued a positive profit alert, forecasting revenue of US$120 million to US$125 million for the first half of 2026, with a net profit of US$62 million to US$67 million for the same period. The strong performance is attributed to ongoing strategic collaborations with global pharmaceutical giants, revenue from out-licensing innovative products and cooperative agreements, and robust growth in its antibody-related business through its subsidiary, Nona Biosciences.Notably, in July, the company entered into a strategic partnership with China's Sinopharm to establish a joint innovation entity. The collaboration will focus on research and development in the field of innovative biologics, with strategic priorities covering areas such as oncology and immuno-inflammatory diseases. Under the terms of the agreement, both parties will share research and development costs and jointly own product rights.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121496757","isCrawlerRequest":true}